Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/348—Cannabaceae
  • A61K36/3486—Humulus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2200/00—Function of food ingredients
  • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
  • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2200/00—Function of food ingredients
  • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
  • A23V2200/332—Promoters of weight control and weight loss
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2300/00—Processes
  • A23V2300/14—Extraction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/30—Extraction of the material
  • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
  • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/30—Extraction of the material
  • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
  • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Definitions

• Yulcho extract is used for the prevention or treatment of metabolic diseases or fatty liver
• the present invention relates to the prevention or treatment of metabolic diseases or fatty liver of Yulcho extract, and more particularly, to prevent or improve metabolic diseases containing yulcho extract as an active ingredient or dietary supplement for weight loss, Yulcho extract
• ⁇ 3> ⁇ sec (Him his japonicus S. et 2.) is also known as hwansam vine or litter grass, which has the effect of lowering the fever, urinating well, eliminating the blood and removing the poison in the body. It treats disease, urinary deficiency, diarrhea, dysentery, pulmonary tuberculosis, pulmonary abscess, pneumonia, leprosy, hemorrhoids, bitter poison and nausea.
• the main herbaceous tree ( ⁇ > ⁇ ) says that it lubricates three seconds, digests five grains, rewards five intestines, kills various insects in the stomach, and controls the whole area.
• Yulcho is a perennial herb that accompanies ginseng and its leaves look like hemp leaves or hop leaves for beer.
• the leaves are opposite each other, and the leaf is long and sweet, and the palms are divided into 5 to 7 branches.
• Leaf fragments have long, elliptical, coarse teeth. Male and female, blooms from May to September, and repeats.
• This vital stem has a lot of stubbornness and a lot of stubborn residue, which can be very itchy and injured when your hands or face are scratched.
• These tough stems also make natural fibers. Bondi is not a plant in Korea, but a plant from other countries long ago, and grows in desolate land.
• Hygiene environment is improved by the improvement of living standard according to the recent economic development, frequent intake of instant food and changes in meat-based diet lead to the accumulation of excessive calorie energy in the body.
• changes in dietary life of modern people have led to a decrease in calorie energy consumption due to lack of exercise, leading to a rapid increase in the obese population.
• the calorie energy accumulated in the body is not only obese, but also various forms of diseases, including metabolic diseases including diabetes, hyperlipidemia and hypertension.
• Obesity is one of the most dangerous and lethal diseases in the 21st century. The reason for this is that obesity is dangerous in itself, but the pressure on the abdomen by fatty tissues often causes constipation, indigestion and gastrointestinal disorders, and it significantly increases the risk of various other diseases. . Obesity increases the risk of obesity, crab type diabetes, hypertension, coronary artery disease, stroke and various cancers (cancer).
• Anti-obesity drugs can be used to treat obesity.
• commercially available anti-obesity drugs have a problem in that side effects appear.
• many products used for obesity medications have side effects and have many social problems.
• Diabetes is a systemic metabolic disease caused by genetic and environmental factors. It is a condition caused by an absolute or relative lack of insulin in the body and refers to an abnormally high level of sugar in the blood. Complications of diabetes include hypoglycemia, ketoacidosis, hyperosmotic complications, macrovascular complications, diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy.
• Hyperlipidemia refers to both hypercholesterolemia and hypertriglyceridemia, cholesterol
• triglycerides (above 200 mg / d) increased above the normal range and are caused by lipoprotein and lipid metabolism disorders.
• Hyperlipidemia is divided into primary hyperlipidemia caused by genetic abnormalities and secondary hyperlipidemia caused by other diseases or drugs such as diabetes. Although there is no particular symptom, the increase in blood cholesterol and triglycerides causes problems such as arteriosclerosis, hypertension, and cardiovascular disease.
• statins can cause nausea, headache, abdominal pain and diarrhea or constipation, which can cause muscle inflammation
• bile acid blockers can reduce the intestinal absorption of vitamins A, D, and K.
• fibric acid derivatives are renal disease It is not suitable for liver disease or gallbladder disease. Therefore, there is an increasing demand for the development of medicines and functional foods containing natural products in place of these preparations (Kook Seung-rae et al., Journal of Family Medicine, 18 (3), pp.317-327, 1997).
• nonalcoholic fatty liver disease has recently been described as atherosclerosis, cerebrovascular disease (Francazani A et al., Am J Med 2008, 121: 72-78), microvascular disease, nephropathy , Cardiovascular disease (CVD), polycystic ovarian syndrome (PC0S), including retinopathy (Targher G et al., Diabetologia 2008; 51 (3): 444-450), and the like. (Targher G et al., Atherosclerosis 2007, 191: 235—240, Cerda C et al., J Hepatol 2007, 47: 412—417), or obstructive sleep apnea (0SA) (Tanne F at al. , Hepatol ogy 2005, 41: 1290-1296).
• Yulcho extract has such efficacy while studying natural extracts without side effects, and completed the present invention.
• an object of the present invention is to provide a dietary supplement for preventing or improving metabolic disorders or a pharmaceutical composition for preventing or treating metabolic disorders, which contains the extract of Yulcho as an active ingredient.
• Another object of the present invention is to provide a use of the extract of Yulcho for the preparation of a prophylactic or therapeutic agent for metabolic diseases.
• Another object of the present invention is to provide a method for preventing or treating metabolic diseases, comprising administering an effective amount of Eulcho extract to a subject in need thereof.
• Another object of the present invention to provide a health functional food for weight loss containing the extract of Yulcho as an active ingredient.
• Another object of the present invention is to provide a dietary supplement for preventing or improving fatty liver or a pharmaceutical composition for preventing or treating fatty liver, which contains the extract of Yulcho as an active ingredient.
• Another object of the present invention is to provide a use for the preparation of an agent for the prevention or treatment of fatty liver of the herb extract.
• Another object of the present invention is to provide a method for preventing or treating fatty liver, comprising administering an effective amount of the extract of Yulcho to an individual in need thereof.
• Another object of the present invention to provide a health functional food for inhibiting the accumulation of visceral fat containing Yulcho extract as an active ingredient.
• the present invention provides a dietary supplement for preventing or improving metabolic disease or a pharmaceutical composition for preventing or treating metabolic disease, comprising the extract of Yulcho as an active ingredient.
• the present invention provides a use of the extract of Yulcho for the preparation of an agent for preventing or treating metabolic diseases.
• the present invention provides a method for preventing or treating metabolic diseases comprising administering to the individual in need thereof an effective amount of the extract.
• the present invention provides a dietary supplement for weight loss, containing the extract as an active ingredient.
• the present invention provides a dietary supplement for preventing or improving fatty liver or a pharmaceutical composition for preventing or treating fatty liver, comprising the extract as an active ingredient.
• the present invention provides a use for the preparation of a therapeutic agent for preventing or treating fatty liver of the herb extract.
• the present invention provides a method for preventing or treating fatty liver, comprising administering to the subject in need thereof an effective amount of the extract.
• the present invention provides a health for inhibiting visceral fat accumulation.
• ⁇ H mlus japonicus Sieboid & Zucc. Is a perennial herbaceous perennial herb that is a common weed in the field. It is rough due to the downward ridges on the main stem and petiole. Flowers bloom in July-August and male and female. The male flower has 5 calyx pieces and stamens, and hangs in the conical inflorescence. The female flower runs in the water inflorescence, and the bract grows after the flower blooms and grows in the shape of a moon. It is 7 ⁇ 10 ⁇ in length. Fruits are fruiting from September to October. Achenes ( ⁇ ) round, brown, round, yellowish brown, with hairs on the top. The bark of the stem is a fiber, the fruit is a high-dry agent, and the fruited starch is used as a diuretic. It is widely distributed in Korea, Japan, China and Taiwan.
• the yulcho has the effect of treating metabolic diseases such as hypertension, obesity, hyperlipidemia and the like.
• metabolic diseases such as hypertension, obesity, hyperlipidemia and the like.
• the Omaco group and the Yulcho administration group showed the median weight of the normal group and the obese control group, even though the Omako group was administered more per day (2g / kg / day), the Yulcho group ( Dosage: lg / kg / day) and the weight is smaller.
• the concentration of triglycerides in blood [Fig. 2]
• the ulcho administration group and the normal group is a similar value
• the LDL level [ Figure 3] is lower than the obesity control group, it can be seen that lower than the omako group. .
• Yulcho extract has a superior effect of preventing deformation and expansion of adipocytes than omako (see FIG. 9).
• the present invention provides a dietary supplement for the prevention or improvement of metabolic diseases or weight loss containing the extract of Yulcho as an active ingredient.
• the present invention is a metabolic disease containing the extract of Yulcho as an active ingredient
• a pharmaceutical composition for prophylaxis or treatment is provided.
• the metabolic disease is characterized in that it is selected from the group consisting of obesity, diabetes, hypertension, hyperlipidemia.
• the present invention has the yulcho extract has a fatty liver prevention or improvement effect. This can be confirmed in ⁇ Example 3> of the present invention. Too much fat can cause fat to accumulate abnormally in the liver, leading to fatty liver.
• the obese control group had a high-fat diet compared to the normal group ingested the normal diet weighs a lot of liver.
• the Yulcho group had a high fat diet, the liver weight was similar to that of the normal group.
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are enzymes present in hepatocytes and used as indicators of liver function tests. When hepatocytes are damaged, they are released into the blood and increase in levels.
• the present invention provides a dietary supplement for preventing or improving fatty liver containing Yulcho extract as an active ingredient.
• the present invention also provides a pharmaceutical composition for preventing or treating fatty liver containing Yulcho extract as an active ingredient.
• Yulcho extract of the present invention also has the effect of inhibiting the accumulation of visceral fat. This can be confirmed in ⁇ Example 4> of the present invention. The more visceral fat, the higher the chance of developing diabetes, heart disease, high blood pressure, the less, the better. Visceral fat weight was measured for mesenteric fat. Referring to FIG. 8, the effect of inhibiting visceral fat accumulation in the urethra administration group can be confirmed. In the obese control group, the amount of visceral fat was excessively increased compared to the normal control group, but the rate of intestinal administration was significantly reduced.
• the present invention provides a health functional food for inhibiting visceral fat accumulation.
• the solvent used in the preparation of the yulcho extract is water, carbon number 1 To 6 alcohols or a mixed solvent thereof, and may be more preferably water.
• the amount of the solvent may vary depending on the amount of vinegar to be extracted, preferably 0.5 to 5 times the volume (w / v »), more preferably 1 to 5 times the volume (w) of the vinegar weight. / v%), and most preferably it can be 1 times the volume (w / v3 ⁇ 4).
• the extract may be used in a liquid phase by filtration, preferably solidified through a drying process of spray drying or lyophilization. More preferably, it may be lyophilized.
• the health functional food of the present invention has all forms of functional foods, nutritional supplements, food additives, etc., which have the effect of preventing or improving metabolic diseases or reducing weight or improving fatty liver.
• Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
• the food may be prepared by drinking the vinegar extract itself in the form of tea, juice and drinks, or may be ingested by granulating, encapsulating and powdering.
• it may be in the form of a composition in combination with the yulcho extract and a known active ingredient known to have a metabolic disease improvement effect or weight loss effect or fatty liver improvement effect.
• the food may include beverages (including alcoholic beverages), fruits and processed foods (e.g., canned fruit, canned foods, jams, marmalade, etc.), fish, meat and processed foods (e.g. ham, sausage cornbeans, etc.). ), Breads, noodles (e.g. udon, soba noodles, ramen noodles, spagate, macaroni, etc.), juices, drinks, cookies, malts, dairy products (e.g. butter, cheese), edible vegetable oils, margarine, vegetable protein , Retort food, ⁇ dongdong food, various seasonings (eg, miso, soy sauce, sauce, etc.) may be prepared by adding the extract of vinegar.
• beverages including alcoholic beverages
• fruits and processed foods e.g., canned fruit, canned foods, jams, marmalade, etc.
• fish meat and processed foods
• meat and processed foods e.g. ham, sausage cornbeans, etc.
• Breads, noodles e.g. udon, soba
• the food additive may include the extract of Yulcho in powder or concentrate form. Yulcho extract content of the food of the present invention can be appropriately adjusted according to the form, use and purpose of the final food, for example, may be about 0.001 ⁇ 20g per 100g of food, but is not limited thereto.
• the food containing the vinegar extract in the present invention may be prepared by mixing with other active ingredients known to have metabolic disease improvement effect or weight loss effect or fatty liver improvement effect.
• the pharmaceutical composition of the present invention may further comprise suitable carriers, excipients, and diluents, which are used alone or in the preparation of pharmaceutical compositions.
• compositions comprising the compounds according to the invention are each acid according to a conventional method.
• Oral formulations such as granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injectable solutions, and may be included in compositions containing compounds.
• Carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, manny, xylly, erythritol, malty, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, celrose, Methyl cellulose, microcrystalline cellulose, polyvinyl pyridone, water, methyl hydroxybenzoate, propyl hydroxy benzoate, talc, magnesium stearate and mineral oil.
• diluents or excipients such as commonly used layering agents, extenders, binders, wetting agents, disintegrating agents and surfactants are used.
• Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may include at least one excipient such as starch, calcium carbonate, sucrose ( sucrose) or lactose, gelatin mixture is prepared.
• excipients such as starch, calcium carbonate, sucrose ( sucrose) or lactose, gelatin mixture is prepared.
• lubricants such as magnesium styrate talc are also used.
• Oral liquid preparations include suspensions, solvents, emulsions, and syrups.
• ком ⁇ онентs such as wetting agents, sweeteners, fragrances, and preservatives may be included. have.
• Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories.
• non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
• As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
• the preferred dosage of the extract of the present invention depends on the condition and congestion of the patient, the severity of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
• the compound of the present invention is preferably administered at 0.1 mg / g to 500 irg / g per day, preferably at 1 mg / g to 200 mg / g. Administration may be administered once a day or may be divided several times. Therefore, the above dosage does not limit the scope of the present invention in any aspect.
• composition of the present invention can be administered to mammals such as mice, mice, livestock, humans, etc. by various routes. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
• the present invention yulcho.
• Large-acid-acid diseases of the extracts are called the liver or liver. It provides a use for the preparation.
• the present invention provides a method for preventing or treating metabolic diseases or fatty liver, comprising administering an effective amount of the extract of Yulcho to an individual in need thereof.
• the metabolic disease is characterized in that it is selected from the group consisting of obesity, diabetes, hypertension, hyperlipidemia.
• Yulcho extract of the present invention itself or a pharmaceutically acceptable salt thereof may be administered in an effective amount via various routes including oral, transdermal, subcutaneous, intravenous or intramuscular.
• the term 'effective amount' refers to an amount that shows a therapeutic and prophylactic effect of a metabolic disease or fatty liver when administered to a patient
• the term 'subject' refers to an animal, preferably a mammal, especially an animal including a human. It may be a cell, tissue, organ, etc. derived from an animal. The subject may be a patient in need of treatment.
• Yulcho extract of the present invention or a pharmaceutically acceptable salt thereof may be administered as it is or may be prepared and administered in various formulations as described above, and preferably, the desired effect, that is, prevention of metabolic diseases Or until a therapeutic effect or a prophylactic or therapeutic effect of fatty liver is derived.
• the compounds of the present invention and their pharmaceutically acceptable salts can be administered by various routes according to methods known in the art. Oral or parenteral, such as oral, intramuscular, intravenous, intradermal, intraarterial, intramedullary, intradural, intraperitoneal, intranasal, intravaginal, intrarectal, sublingual or subcutaneous, gastrointestinal tract, mucosal or respiratory May be administered.
• the method of applying the yulcho extract of the present invention or a pharmaceutically acceptable salt thereof directly to the skin, or preparing the yulcho extract as an injectable formulation and injecting a predetermined amount into the lower layer of the skin with a 30 gauge thin needle It can be administered by lightly pricking the skin with an injection needle. Preferably it can be applied directly to the skin.
• the lyocholic extract of the present invention and a pharmaceutically acceptable salt thereof may be administered in a form encapsulated in or encapsulated in a molecule that causes high affinity binding to a target cell or tissue (eg, skin cells or skin tissue).
• Yulcho extract of the present invention and its pharmaceutically acceptable salts can be prepared using sterols (e.g.
• lipids e.g. cationic lipids, virosomes or liposomes
• target cells using techniques known in the art.
• Specific binding agents eg, ligands recognized by target cell specific receptors.
• Suitable coupling or crosslinking agents can include, for example, Protein A, carbodiimide, N-succinimidyl-3- (2-pyridyldithio) propioate (SPDP) and the like.
• SPDP N-succinimidyl-3- (2-pyridyldithio) propioate
• the present invention relates to a composition for the prevention or treatment of metabolic diseases containing Yulcho extract as an active ingredient, and more particularly, to prevent or improve metabolic diseases containing Yulcho extract as an active ingredient, or health functional food for weight loss.
• the pharmaceutical composition for the prevention or treatment of metabolic diseases containing the extract of Yulcho as an active ingredient, the health functional food or pharmaceutical composition for the prevention or improvement of fatty liver containing the extract of Yulcho as an active ingredient, the intestine containing the extract of Yulcho as an active ingredient It relates to a dietary supplement for inhibiting fat accumulation. Yulcho extract of the present invention reduces body weight, lowers blood lipid concentration, and lowers ALT and AST levels. It also has the effect of inhibiting the accumulation of visceral fat. By using this effect, it is effective in the manufacture of health functional foods that prevent or improve metabolic diseases, fatty liver, visceral fat accumulation, and the like.
• 1 is a graph comparing the change in weight of each experimental group.
• Figure 2 is a graph comparing the blood TG concentration of each experimental group. (Y-axis unit: mg / dl
• I X-axis Nomal (normal group), ControK obesity control group), Omacor (omako-administered group), Yulcho (yolin herb administration group))
• Figure 3 is a graph comparing the LDL concentration in the blood of each experimental group. (Y-axis unit: mg / dl
• I X-axis NomaK normal group
• Control obesity control group
• Omacor Opacor
• Yulcho Yulcho-administered group
• IX axis Nomal (normal group), Control (obesity control group), Omacor (Omako-administered group), Yulcho (yorchorus-treated group) ⁇ 71>
• Y-axis unit mg / dl I
• X-axis Nomal (normal group), Control (obesity control group), Omacor (Omako-administered group), Yulcho (Yulcho administration group))
• Figure 6 is a graph comparing the liver weight of each experimental group.
• Y-axis unit g (grams)
• I X-axis Nomal (normal group), Control (obesity control group), Omacor (omako-administered group), Yulcho (yield-administered group))
• FIG. 7A is a graph comparing the ALT level in serum of each experimental group.
• IU / L I X-axis NomaK normal group), Control (obesity control group), Omacor (Omako-administered group), Yulcho (Yulcho-administered group))
• FIG. 7B is a graph comparing the serum AST level of each experimental group. (Y-axis unit :
• IU / L I X-axis Nomal (normal group), ControK obesity control group, Omacor (omako-administered group), Yulcho (yulcho-administered group))
• Y-axis unit g (grams)
• I X-axis Nomal (normal group), Control (obesity control group), Omacor (omako-administered group), rate second (rate-choled group))
• Figure 9 is a photograph of the subcutaneous fat tissue section of the inguinal region of the experimental animal. (A-normal control group, B-obesity control group, C-omako administration group, D-Yulcho extract administration group)
• FIG. 10 is a photograph of a liver tissue section of an experimental animal, in which a red portion represents lipids.
• FIG. (A-normal control group, B-obesity control group, C-omako administration group, D-lychee extract administration group)
• Yulcho (Uri Pharmaceutical, Seoul) lOOOOg was ground to a size of 30 mesh and put in water ⁇ and heated at locrc for 2 hours. After heating, the mixture was left for 1 hour to remove 10% of the inferior liquor (such as impurity heavy metals), and the supernatant was recovered and lyophilized to prepare 100 g of rate extract.
• mice were randomly divided into 10 mice and divided into experimental groups shown in Table 1 below. Samples from each experimental group were administered orally once a day. In addition, the normal group fed the normal diet only for 12 weeks, and the rest of the experimental groups fed the high-fat diet containing 60% fat (Research diets, D12492) for 12 weeks.
• Omacor supplied to the Omaco-administered group, is a high-purity DHA-containing product developed by Pronova, Norway. As a prophylactic agent, it has been shown to reduce the triglyceride level to 45% for patients with high triglycerides, and to reduce cardiovascular mortality by more than 30% when taken as a secondary preventive measure after myocardial infarction. All.
• Weight was measured twice a week.
• the average value of the weight measured twice a week is shown as a graph in [FIG. 1].
• the obese control group significantly increased its weight compared to the normal group. Yulcho group showed similar mean value as the Omaco group. Considering that the dose of omako is twice the rate of yulcho, it can be seen that the efficacy of yulcho is superior to omako.
• HDLC high density lipoprotein cholesterol / Selective elimination (Wako Ind, Japan)
• LDL low density lipoprotein cholesterol / measurement: Lactate to pyruvate
• TC total cholesterol / content: Enzymatic (Backman Coulter, Ireland)
• TG triglyceride / content measurement method: Enzymatic (Wako Ind, Japan)
• Subcutaneous fat was extracted from the inguinals of the experimental animals, fixed in 10% aqueous solution of Formalin, and frozen and sliced into 4 ⁇ m thick. Section tissues were stained in Hematoxylin & Eosin solution and observed under a microscope. The results are shown in FIG. 9.
• the adipocytes show only the nucleus in the intracellular contents (dark dots).
• the adipocytes are small in size and can find nuclei in most adipocytes.
• the cells are much larger in size than the normal control group, and there are a large number of cells without nuclei. As fat cells are enlarged in a limited space, the surrounding adipose tissue is broken and the nucleus is lost.
• the omako-administered group was not different from the obese control group, but the vinegar extract-administered group was significantly smaller in size than the obese control group and the omako-administered group, and the number of normal fat cells was also significantly higher. ⁇ 114>
• the animals were fasted for 12 hours before sacrifice, inhaled with ether, anesthetized, and then opened along the abdominal midline, followed by blood loss in the abdominal aorta, followed by 4 ° C physiology through the portal vein.
• the liver was perfused with saline to remove blood remaining in the tissue. Thereafter, the liver was extracted, and the extracted liver was washed with physiological saline, and the physiological saline remaining in the organ was removed and weighed.
• Example 3-1 After fixing the liver extracted in Example 3-1 in a 10% aqueous solution of Formalin, it is frozen and sectioned to a thickness of 10um. The sections were stained with Hematoxylin & Eosin solution, and then stained with Lipid only by Oil red 0 solution staining. The photograph observed with the microscope was described in FIG.
• the present invention relates to a composition for the prevention or treatment of metabolic diseases containing Yulcho extract as an active ingredient, and more particularly, to prevent or improve metabolic diseases containing Yulcho extract as an active ingredient, or health functional food for weight loss.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Mycology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Botany (AREA)
• Food Science & Technology (AREA)
• Nutrition Science (AREA)
• Polymers & Plastics (AREA)
• Alternative & Traditional Medicine (AREA)
• Epidemiology (AREA)
• Microbiology (AREA)
• Medical Informatics (AREA)
• Biotechnology (AREA)
• Pediatric Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Gastroenterology & Hepatology (AREA)
• Child & Adolescent Psychology (AREA)
• Medicines Containing Plant Substances (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=49117059

Family Applications (1)

Country Status (6)

Cited By (1)

Families Citing this family (7)

Citations (7)

Family Cites Families (6)

• 2012
  • 2012-03-07 KR KR1020120023431A patent/KR101523812B1/ko active Active
• 2013
  • 2013-03-07 CN CN201380023708.2A patent/CN104320981A/zh active Pending
  • 2013-03-07 EP EP13757825.8A patent/EP2823717B1/en active Active
  • 2013-03-07 IN IN8240DEN2014 patent/IN2014DN08240A/en unknown
  • 2013-03-07 WO PCT/KR2013/001862 patent/WO2013133649A1/ko not_active Ceased
• 2014
  • 2014-09-08 US US14/480,027 patent/US10137160B2/en active Active

Patent Citations (7)

Non-Patent Citations (10)

Also Published As

Similar Documents

Legal Events